Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors

RMD Open

Volumn 3, Issue 1, 2017, Pages

  Strand, Vibeke ^a   Reaney, Matthew ^b   Chen, Chieh I ^c   Proudfoot, Clare W J ^b   Guillonneau, Sophie ^d   Bauer, Deborah ^d   Mangan, Erin ^c   Graham, Neil M H ^c   Van Hoogstraten, Hubert ^d   Lin, Yong ^d   Pacheco Tena, César ^e   Fleischmann, Roy ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sanofi   (United Kingdom)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d SANOFI   (France)

^e UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA   (Mexico)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; SARILUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FACIT-FATIGUE; FAMILY; FATIGUE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PAIN; PAIN AND MORNING STIFFNESS VISUAL ANALOG SCALE; PATIENT-REPORTED OUTCOME; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS IMPACT OF DISEASE; SCORING SYSTEM; SHORT FORM 36; SOCIAL BEHAVIOR; VISUAL ANALOG SCALE; WORK; WORK PRODUCTIVITY SURVEY;

EID: 85035311704     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000416     Document Type: Article

References (34)

1. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2005; 32:2250-6.
2. Kirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10 - conceptualizing methods for developing patient-reported outcomes. J Rheumatol 2011; 38:1699-701.
3. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/06/WC500187583.pdf (accessed 14 Nov 2016).
4. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36:729-40.
5. Ahlmen M, Nordenskiold U, Archenholtz B, et al. Rheumatology outcomes: the patient's perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) 2005; 44:105-10.
6. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol 2010; 28:S32-40.
7. Rendas-Baum R, Bayliss M, Kosinski M, et al. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective. Curr Med Res Opin 2014; 30:1391-403.
8. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44:123-30.
9. Potocky T, Rafique A, Fairhurst J, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor alpha (il-6ra) [abstract]. Mod Rheumatol 2016; 26(Suppl):S69-70.
10. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010; 2:247-56.
11. Schaible HG Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther 2014; 16:470.
12. Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci 2012; 1261:88-96.
13. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III study. Arthritis Res Ther 2016; 18:198.
14. Fleischmann R, van Adelsberg J, Lin SL, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheum. 2017; 69:277-90.
15. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-81.
16. Ware JE Jr, Kosinski M, Bjorner JB, et al. User's manual for the SF-36v2™ health survey, 2nd edn. Lincoln, RI: Quality Metric Incorporated, 2007.
17. Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32:811-19.
18. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009; 11: R73.
19. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 2011; 70:935-42.
20. Vliet Vlieland TP, Zwinderman AH, Breedveld FC, et al. Measurement of morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol 1997; 50:757-63.
21. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-87.
22. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20:557-60.
23. Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011; 38:1720-7.
24. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73:86-94.
25. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63:609-21.
26. Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011; 70:996-1002.
27. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9:105-21.
28. Lubeck DP Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004; 22:27-38.
29. Dougados M, Brault Y, Logeart I, et al. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther 2012; 14:R129.
30. Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003; 62:316-21.
31. van Steenbergen HW, Tsonaka R, Huizinga TW, et al. Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open 2015; 1:e000041.
32. Hewlett S, Carr M, Ryan S, et al. Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 2005; 3:131-42.
33. Nikolaus S, Bode C, Taal E, et al. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013; 65:1128-46.
34. Tang K, Beaton DE, Boonen A, et al. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken) 2011; 63(suppl 11):S337-49.